STOCK TITAN

[6-K] QIAGEN N.V. Current Report (Foreign Issuer)

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
6-K
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

__________________________________

FORM 6-K
 
__________________________________
 
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under
the Securities Exchange Act of 1934
For the quarterly period ended June 30, 2025
Commission File Number 001-38332
 __________________________________
QIAGEN N.V.
(Translation of registrant’s name into English)
 __________________________________
Hulsterweg 82
5912 PL Venlo
The Netherlands
(Address of principal executive office)
 __________________________________
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F  ý            Form 40-F  o

1

Table of Contents
QIAGEN N.V.
Form 6-K

TABLE OF CONTENTS
 
ItemPage
Other Information
3
Signatures
4
Exhibit Index
5

2

Table of Contents
OTHER INFORMATION
For the three and six months ended June 30, 2025, QIAGEN N.V. prepared its quarterly report under United States generally accepted accounting principles (U.S. GAAP). This quarterly report is furnished herewith as Exhibit 99.1 and incorporated by reference herein.




3

Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
QIAGEN N.V.
By:/s/ Roland Sackers
 Roland Sackers
 Chief Financial Officer

Date: August 21, 2025

4

Table of Contents
EXHIBIT INDEX
 
Exhibit
No.
  Exhibit
99.1
  
U.S. GAAP Quarterly Report for the Period Ended June 30, 2025


5
Qiagen

NYSE:QGEN

QGEN Rankings

QGEN Latest News

QGEN Latest SEC Filings

QGEN Stock Data

10.67B
212.96M
1.61%
87.56%
3.04%
Diagnostics & Research
Healthcare
Link
Netherlands
Venlo